United Therapeutics Corp. (UTHR: Quote) Thursday reported filing a lawsuit against Sandoz Inc. which seeks to block the approval of an Abbreviated New Drug Application, or ANDA, for the marketing of a generic version of United Therapeutics's product Remodulin.
Sandoz, a subsidiary of Novartis AG (NVS: Quote), claims in its ANDA that three US patents relating to Remodulin are "not valid, not enforceable" and cannot be infringed by production of a generic version.
Further, the US Food and Drug Administration, or FDA, is automatically precluded from approving the ANDA for up to 30 months as a result of the filing, which occurred within 45 days of Sandoz filing its application.
Click here to receive FREE breaking news email alerts for United Therapeutics Corp and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.com
Business News